Search - tctmd.com

Displaying 21 - 28 of 28

Sort: Relevancy | Date

News Conference News EuroPCR 2016

Last Window for BMS Closes as LEADERS-FREE Supports DES in High-Bleeding-Risk ACS

Michael O'Riordan

May 17, 2016

News Conference News EuroPCR 2016

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Yael L. Maxwell

May 17, 2016

News Conference News EuroPCR 2016

‘Signal’ of Poor Durability Seen With First-Generation TAVR Devices

Caitlin E. Cox

May 17, 2016

News Conference News EuroPCR 2015

DEFLECT III: 30-Day Results Show Successful, Safe TAVR With Novel Neuroprotection Device

Yael L. Maxwell

May 20, 2015

News Conference News EuroPCR 2014

Benefit of LAA Closure Becomes Most Evident After 1 Year

Caitlin E. Cox

May 23, 2014

News Conference News EuroPCR 2014

Early Data Show Novel Catheter-Implanted Device Benefits Patients with Left Heart Failure

Caitlin E. Cox

May 22, 2014

Presentation EuroPCR 2014

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Presenter: Jos? Ram?n L?pez-M?nguez

May 21, 2014

News Conference News EuroPCR 2013

Registry Questions Superiority of Bivalirudin Over Heparin Alone in NSTE-ACS

Yael L. Maxwell

May 23, 2013

Advertisement

Last Window for BMS Closes as LEADERS-FREE Supports DES in High-Bleeding-Risk ACS

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

‘Signal’ of Poor Durability Seen With First-Generation TAVR Devices

DEFLECT III: 30-Day Results Show Successful, Safe TAVR With Novel Neuroprotection Device

Benefit of LAA Closure Becomes Most Evident After 1 Year

Early Data Show Novel Catheter-Implanted Device Benefits Patients with Left Heart Failure

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Registry Questions Superiority of Bivalirudin Over Heparin Alone in NSTE-ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content